Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M11,103Revenue (TTM) $M1,134Net Margin (%)--Altman Z-Score--
Enterprise Value $M--EPS (TTM) $-6.5Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M63.7ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with SLXP

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SLXPJohn Paulson 2015-06-30 Sold Out -4.99%$172.81 - $172.81
($172.81)
$ 172.810%Sold Out0
SLXPMario Gabelli 2015-06-30 Sold Out -0.4%$172.81 - $172.81
($172.81)
$ 172.810%Sold Out0
SLXPGeorge Soros 2015-06-30 Sold Out -0.39%$172.81 - $172.81
($172.81)
$ 172.810%Sold Out0
SLXPMario Gabelli 2015-03-31 Buy 0.4%$112.84 - $172.81
($146.8)
$ 172.8118%New holding442,350
SLXPGeorge Soros 2015-03-31 Reduce-0.37%$112.84 - $172.81
($146.8)
$ 172.8118%Reduce -58.92%201,903
SLXPFirst Eagle Investment 2015-03-31 Buy 0.2%$112.84 - $172.81
($146.8)
$ 172.8118%New holding479,891
SLXPJohn Paulson 2015-03-31 Reduce-0.18%$112.84 - $172.81
($146.8)
$ 172.8118%Reduce -5.27%5,500,000
SLXPRuane Cunniff 2015-03-31 Buy 0.02%$112.84 - $172.81
($146.8)
$ 172.8118%New holding20,000
SLXPJohn Paulson 2014-12-31 Buy 3.4%$91.47 - $152.87
($120.33)
$ 172.8144%New holding5,806,000
SLXPGeorge Soros 2014-12-31 Buy 0.62%$91.47 - $152.87
($120.33)
$ 172.8144%New holding491,531
SLXPVanguard Health Care Fund 2014-12-31 Sold Out -0.61%$91.47 - $152.87
($120.73)
$ 172.8143%Sold Out0
SLXPVanguard Health Care Fund 2014-09-30 Reduce-0.09%$127.75 - $169.17
($144.97)
$ 172.8119%Reduce -15.70%1,538,045
SLXPJoel Greenblatt 2014-06-30 Sold Out -0.48%$97.7 - $125.07
($110.33)
$ 172.8157%Sold Out0
SLXPVanguard Health Care Fund 2014-06-30 Reduce-0.06%$97.7 - $125.07
($110.42)
$ 172.8157%Reduce -10.25%1,824,545
SLXPJoel Greenblatt 2014-03-31 Buy 0.48%$88.8 - $114.64
($101.95)
$ 172.8170%New holding307,445
SLXPVanguard Health Care Fund 2014-03-31 Reduce-0.03%$89.09 - $114.64
($102.39)
$ 172.8169%Reduce -5.36%2,032,845
SLXPJoel Greenblatt 2013-09-30 Sold Out -0.36%$65.73 - $75.54
($68.97)
$ 172.81151%Sold Out0
SLXPJoel Greenblatt 2013-06-30 Buy 0.36%$47.72 - $66.83
($57.19)
$ 172.81202%New holding127,495
SLXPJoel Greenblatt 2013-03-31 Sold Out -0.15%$40.472 - $51.37
($47.96)
$ 172.81260%Sold Out0
SLXPVanguard Health Care Fund 2013-03-31 Add0.08%$40.472 - $51.37
($47.96)
$ 172.81260%Add 22.44%2,147,945
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SLXP is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SLXP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Forbes William PPresident, Medical R&D and CDO 2015-03-09Sell42,880$157.849.48view
CREECH TIMOTHY JSee Remarks 2015-03-06Sell4,600$157.679.6view
Scruggs Rick DExecutive Vice President 2015-03-06Sell4,000$157.559.69view
Forbes William PEVP Research&Devel & CDO 2015-03-06Sell20,000$157.969.4view
Forbes William PEVP Research&Devel & CDO 2014-11-12Sell11,079$95.0581.81view
CREECH TIMOTHY JSee Remarks 2014-11-05Sell0$081.81view
LOGAN CAROLYN JPresident & CEO 2014-06-26Sell53,057$123.3840.06view
Scruggs Rick DExecutive Vice President 2014-05-16Sell900$105.6763.54view
D ALONZO THOMASDirector 2014-04-22Sell11,530$110.8955.84view
CHAPPELL JOHN FDirector 2014-03-04Sell10,000$112.254.02view

Press Releases about SLXP :

Quarterly/Annual Reports about SLXP:

    News about SLXP:

    Articles On GuruFocus.com
    Does M&A Still Have a Future in Big Pharma? Oct 27 2015 
    GAMCO Investors' Largest Sales During Second Quarter Sep 14 2015 
    First Eagle Fund Of America 2Q Commentary Aug 11 2015 
    Ruane Cunniff Adds New Positions to Portfolio In Q1FY15 May 18 2015 
    Locust Wood Capital Bet on Top Performer Valeant Pharmaceuticals May 14 2015 
    Jean-Marie Eveillard Buys Flowserve, W W Grainger May 11 2015 
    Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
    This Week’s Pharma Highlights Mar 19 2015 
    Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
    Valeant Pharma Acquires Salix Mar 18 2015 

    More From Other Websites
    Valeant missed huge on its 'billion dollar' savior drug — that should raise a big red flag Mar 15 2016
    How Salix/Sprout affected Valeant's earnings Mar 15 2016
    Valeant Says It's Under Investigation by SEC, Shares Plunge Feb 29 2016
    Where Salix fits in Valeant’s earnings restatement Feb 23 2016
    Valeant Has Risk Of New Undisclosed SEC Probe, Report Says Feb 23 2016
    SEC Investigating Ex-Salix Executives Over Misleading Investors Feb 10 2016
    SEC investigating former Salix Pharma execs, Reuters reports Feb 09 2016
    SEC probes former Salix CEO, CFO over investor disclosure-source Feb 09 2016
    BMRA: Q2 Results, IBS Advisory Board Beefed Up Further Jan 19 2016
    Pharming And Salix Announce First Patient Treated In Clinical Study Of Ruconest® For Prophylaxis Of... Jan 12 2016
    Salix, Sprout parent Valeant Pharma picks interim CEO Jan 06 2016
    Piper Jaffray: Valeant's Business Could Be Broken Up In 2016 Dec 18 2015
    Valeant launches direct to consumer ads with former Salix IBS drug Oct 27 2015
    The CEO of controversial drug giant Valeant sent this letter to employees after its stock plunged... Sep 28 2015
    Valeant Pharmaceuticals (VRX) Earnings Report: Q2 2015 Conference Call Transcript Jul 23 2015
    Valeant profit beats estimates as U.S. sales stay strong Jul 23 2015
    Valeant Pharmaceuticals Gets FDA Nod for Xifaxan for IBS-D - Analyst Blog May 28 2015
    Big name investors take sides on Ackman bet on Valeant: filings May 15 2015
    JetBlue Airways Corporation (JBLU), Twenty-First Century Fox Inc (FOX): CQS Cayman’s Top Picks for... May 14 2015
    Valeant raises outlook after completing purchase of Salix Apr 29 2015
    Drugmaker Valeant completes $11 billion purchase of Salix Apr 01 2015
    Synergy Pharma exploring sale - Bloomberg Mar 26 2015
    Valeant increases Salix bid; Endo pulls out of bidding Mar 16 2015
    Endo bid for Salix threatens Valeant deal Mar 11 2015
    US STOCKS-Wall Street slips off Dow, S&P records as oil price drops Feb 23 2015
    Drugmaker Valeant close to buying Salix - source Feb 20 2015
    Valeant in talks to buy Salix Pharma - Bloomberg Feb 03 2015
    US STOCKS-Wall St flat as healthcare offsets energy Nov 07 2014
    US STOCKS-Wall St dips after payrolls, but uptrend seen intact Nov 07 2014
    US STOCKS-Salix Pharma, Zynga among biggest premarket movers Nov 07 2014
    US stocks rise on strong September jobs report Oct 03 2014
    US STOCKS-Salix jumps after terminated merger deal, upgrade Oct 03 2014
    BUZZ-U.S. Stocks on the Move-Facebook, Salix, UBS Oct 03 2014
    US stocks mixed as European equities tumble Sep 23 2014
    FDA approves AstraZeneca, Nektar constipation drug Sep 16 2014
    Allergan approaches Salix to fight Valeant bid Aug 19 2014

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)